Company Analysis Applied Therapeutics
1. Summary
Advantages
- Price (0.5367 $) is less than fair price (3.59 $)
- Current debt level 2.24% is below 100% and has decreased over 5 years from 4.21%.
- The company's current efficiency (ROE=698.49%) is higher than the sector average (ROE=-82.41%)
Disadvantages
- Dividends (0%) are below the sector average (1.31%).
- The stock's return over the last year (-91.95%) is lower than the sector average (-33.71%).
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Applied Therapeutics | Healthcare | Index | |
|---|---|---|---|
| 7 days | 5.3% | -1.2% | 1.2% |
| 90 days | -37% | -30% | -5.2% |
| 1 year | -92% | -33.7% | 9.5% |
APLT vs Sector: Applied Therapeutics has significantly underperformed the "Healthcare" sector by -58.24% over the past year.
APLT vs Market: Applied Therapeutics has significantly underperformed the market by -101.46% over the past year.
Stable price: APLT is not significantly more volatile than the rest of the market on "New York Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: APLT with weekly volatility of -1.77% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (0.5367 $) is lower than the fair price (3.59 $).
Price significantly below the fair price: The current price (0.5367 $) is 568.9% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (114.26).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (73.05).
4.3. P/BV
P/BV vs Sector: The company's P/BV (-14.84) is lower than that of the sector as a whole (9.02).
P/BV vs Market: The company's P/BV (-14.84) is lower than that of the market as a whole (22.32).
4.4. P/S
P/S vs Sector: The company's P/S indicator (25.46) is higher than that of the sector as a whole (4.1).
P/S vs Market: The company's P/S indicator (25.46) is higher than that of the market as a whole (15.91).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-3.21) is lower than that of the sector as a whole (17.72).
EV/Ebitda vs Market: The company's EV/Ebitda (-3.21) is lower than that of the market as a whole (23.05).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 5.49% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (5.49%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-50.52%).
5.4. ROE
ROE vs Sector: The company's ROE (698.49%) is higher than that of the sector as a whole (-82.41%).
ROE vs Market: The company's ROE (698.49%) is higher than that of the market as a whole (25.12%).
5.5. ROA
ROA vs Sector: The company's ROA (-218.41%) is lower than that of the sector as a whole (6.75%).
ROA vs Market: The company's ROA (-218.41%) is lower than that of the market as a whole (6.65%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.68%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.31%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.31%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
